Each patient must meet all of the following inclusion criteria to be enrolled in the
study:

Inclusion Criteria:

- Patients with previously untreated DLBCL that has been sub classified as the non-GCB
subtype.

- At least 1 measurable tumor mass.

- Availability of paraffin block with sufficient tumor tissue.

- No evidence of central nervous system lymphoma.

- Eastern Cooperative Oncology Group (ECOG) performance status of < or equal to 2.

- Female patients who are post menopausal, surgically sterile, or agree to practice 2
effective methods of contraception or abstain from heterosexual intercourse.

- Male patients who agree to practice effective barrier contraception or agree to
abstain from heterosexual intercourse.

Patients meeting any of the following exclusion criteria are not to be enrolled in the
study:

Exclusion Criteria:

- Diagnosed or treated for a malignancy other than DLBCL within 2 years of first dose
or evidence of active malignancy other than DLBCL.

- Peripheral neuropathy of Grade 2 or greater.

- Known history of human immunodeficiency virus (HIV) infection, unless receiving
highly active antiretroviral therapy (HAART).

- Active infection requiring systemic therapy.

- Major surgery within 2 weeks before first dose.

- Patients with a left ventricular ejection fraction (LVEF) or less than 45%.

- Myocardial infarction with 6 months of enrollment or evidence of current uncontrolled
cardiovascular conditions as described in the protocol.

- History of allergic reaction/ hypersensitivity attributable to boron, mannitol,
polysorbate 80 or sodium citrate dehydrate, or anaphylaxis or immunoglobulin E
(IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab.